Antiresorptive drugs and dental implants: practical steps for the busy clinic

A new Periodontology 2000 review reminds us that antiresorptive drugs change the biology around implants — the message to the chair: screen, stratify, control inflammation early, and plan maintenance with the patient and prescriber.

A fresh review in Periodontology 2000 examines how antiresorptive therapies (bisphosphonates and denosumab) affect peri‑implant tissues and clinical outcomes and outlines practical implications for implant care. The authors stress that these drugs suppress osteoclast activity, alter bone remodelling and immune responses, and therefore change how peri‑implant inflammation and healing may evolve. They conclude that early control of peri‑implant inflammation, individualised risk stratification, and strict supportive maintenance should be central to management. ([arxivlens.com](

How common and how dangerous? For patients taking low‑dose oral bisphosphonates for osteoporosis the absolute risk of medication‑related osteonecrosis of the jaw (MRONJ) after dental procedures remains low in population studies, while higher risks are reported for cancer patients receiving high‑dose intravenous antiresorptives. Major society guidance therefore recommends completing necessary dental treatment before high‑dose antiresorptive therapy begins and avoiding elective implants in oncology patients on IV therapy. For osteoporosis patients, the evidence is weaker and inconsistent: several systematic reviews find no clear increase in implant failure with usual osteoporosis dosing, but the data have important limitations. Clinical decisions should therefore be driven by individual risk, not a blanket rule. ([aaoms.org](

What to do when the patient sits in your chair (practical checklist you can use now). 1) Take a specific drug history: name (alendronate, risedronate, zoledronate, denosumab/Prolia/Xgeva), route (oral vs IV), dose and indication (osteoporosis vs cancer), start date and last dose. 2) Communicate with the prescriber for patients on IV antiresorptives or denosumab for cancer: elective implants are discouraged and any surgical plan must be multidisciplinary. 3) For osteoporotic patients on oral bisphosphonates or denosumab for fracture prevention, do a risk stratification that weighs drug type/duration, periodontal status, smoking, diabetes and need for grafting; discuss risks and obtain informed consent. 4) If you proceed, minimise invasive bone trauma, control infection before surgery and schedule closer follow‑up. Drug holidays should not be initiated or stopped by the dentist alone; evidence for benefit is limited and the decision rests with the prescribing physician. ([pubmed.ncbi.nlm.nih.gov](

Prevention beats cure: peri‑implant inflammation may be the key trigger for implant‑related bone necrosis in patients on antiresorptives. That means strict plaque control, early treatment of mucositis, and a proactive maintenance programme are your best defence. If peri‑implantitis develops, expect a more complex course: the literature includes case reports and series where peri‑implant infection preceded MRONJ or implant sequestration, and controlled trials on therapy outcomes in antiresorptive‑exposed patients are scarce. So act early, escalate treatment sooner than you might for a low‑risk patient, and coordinate with the patient’s physician. ([pmc.ncbi.nlm.nih.gov](

How to discuss risk with patients (short scripts). For an osteoporotic patient on oral bisphosphonate: “Your fracture medicine slightly changes bone healing, but current studies do not show a large rise in implant failure at typical doses; we can proceed if we reduce infection risk and follow you closely.” For a patient on IV antiresorptives for cancer: “Because this treatment carries a higher risk of jaw bone problems, we recommend dental clearance before therapy and normally avoid elective implants while you’re on the drug.” Always document the discussion and the planned maintenance schedule. ([aaoms.org](